25.04.2013
- Biogen reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming...
22.04.2013
- The board of Irish drugmaker Elan unanimously rejected a formal bid from Royalty Pharma on Monday, saying the U.S. investment firm's offer of $11.25 a share grossly undervalues the...
19.04.2013
- U.S. healthcare firm Johnson & Johnson cut its stake in Elan on Thursday in a move that clouds prospects for a $7.3 billion takeover bid for the Irish drugmaker. U.S. investment...
12.04.2013
- U.S. investment firm Royalty Pharma is considering sweetening its $6.6 billion offer for Irish drugmaker Elan by paying Elan shareholders more if the multiple sclerosis drug...
22.03.2013
- European regulators have recommended approval of two new multiple sclerosis pills from Biogen and Sanofi, both of which are expected to become major sellers. Friday's decision by...
25.02.2013
- Investment firm Royalty Pharma has made a $6.6 billion bid approach to Elan, seeking to scupper the Irish drugmaker's plan to spend most of the proceeds from a major drug sale on...
06.02.2013
- Biogen is to take full ownership of blockbuster multiple sclerosis drug Tysabri after agreeing to pay Irish partner Elan $3.25 billion plus future royalties on sales of the drug...
16.01.2013
- Drugmakers are betting that a new wave of medicines for cancer, diabetes, heart disease, multiple sclerosis and hepatitis will shape up as tomorrow's blockbusters in the coming 12...
